• DPPH Assay for Natural Product Decisions

  2026-09-29

  DPPH (2,2-Diphenyl-1-Picrylhydrazyl) provides more than a rapid antioxidant readout: it can act as a decision gate for natural-product prioritization. This article explains how to interpret its chemistry, integrate it with orthogonal assays, and avoid mistaking radical scavenging for cellular efficacy.

• hly Deletion Reshapes Listeria Biofilms and Sensitivity

  2026-09-28

  A 2026 study used an hly deletion mutant to show that hemolysin is linked not only to virulence but also to Listeria monocytogenes biofilm architecture, adhesion-related traits, regulatory gene expression, and antibiotic response. The findings support a model in which hly-associated pathways contribute to environmental persistence and identify biofilm disruption as an important consequence of targeted genetic perturbation.

• Olfactory GnRH3 Neurons Link Pheromones to Courtship

  2026-09-28

  A zebrafish study identifies olfactory epithelial GnRH3 neurons as a sensory route for detecting a post-ovulatory pheromone and connecting that signal with male courtship. Anatomical, neuronal-response, genetic and behavioral findings support a role for this population in reproductive success, while leaving important questions about receptor-level signaling and transfer to other species.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-09-27

  A drug screen reported that ATRX-deficient high-grade glioma cells were more vulnerable to multi-targeted receptor tyrosine kinase and selected PDGFR inhibitors than ATRX-proficient counterparts. The study also found pronounced toxicity from combining RTK inhibition with temozolomide in ATRX-deficient cells, supporting further evaluation of ATRX status as a biomarker rather than establishing a treatment recommendation.

• Benzyl-activated Streptavidin Magnetic Beads for I/R

  2026-09-26

  Translate time-resolved annexin-V findings in cardiac ischemia/reperfusion into practical ex vivo enrichment workflows—without confusing bead capture with in vivo cell-death imaging. This guide covers bead setup, starting protocol conditions, assay choices, and troubleshooting for biotinylated targets.

• MT2A Promotes Apoptosis in HL60 Leukemia Cells

  2026-09-25

  In HL60 acute myeloid leukemia cells, MT2A overexpression reduced proliferative capacity, increased apoptosis, and promoted G2/M-phase arrest, while MT2A interference increased proliferation. The study links these effects to changes in apoptosis-associated proteins and NF-κB pathway readouts, providing a cell-model basis for investigating MT2A in AML rather than proof of a clinical therapeutic effect.

• Prochlorperazine-Induced NMS: Clinical Lessons

  2026-09-25

  This case report describes neuroleptic malignant syndrome (NMS) in an older adult after standard-dose prochlorperazine, with characteristic clinical signs but only modest creatine phosphokinase elevation. It emphasizes medication history and evolving bedside findings as essential diagnostic evidence, and documents improvement after lorazepam and amantadine treatment.

• Thiothixene: Antipsychotic and Efferocytosis Evidence

  2026-09-24

  Thiothixene is a typical antipsychotic agent with dopamine D2 and serotonin 5-HT2A receptor antagonism, and product information also describes its use in macrophage efferocytosis research. The available evidence supports distinct clinical pharmacokinetic and preclinical immunology contexts; it does not establish that findings in one context predict outcomes in the other.

• RG7388: A Practical MDM2 Antagonist Workflow

  2026-09-24

  RG7388 offers a potent way to probe how blocking MDM2 can restore p53 activity in wild-type TP53 cancer models. This guide connects practical assay design to a colorectal-cancer chemoradiotherapy study while clarifying what that study does—and does not—show about RG7388.

• Nintedanib (BIBF 1120) in ATRX-Deficient Glioma

  2026-09-23

  Use Nintedanib to test how broad VEGFR, FGFR, and PDGFR blockade affects angiogenic signaling and cancer-cell responses. An ATRX-focused workflow helps distinguish a promising pathway-level hypothesis from evidence that has not yet established Nintedanib as an ATRX-selective glioma treatment.

• (-)-Blebbistatin and Heat-Responsive Cardiac Biology

  2026-09-23

  The discovery that HCN4 couples temperature to cardiac pacemaker activity creates a compelling framework for testing how membrane excitability interacts with cytoskeletal force. This thought-leadership guide positions (-)-Blebbistatin as a reversible non-muscle myosin II inhibitor for separating actomyosin-dependent mechanics from HCN4-driven electrical responses, while emphasizing controls, translational boundaries, and assay strategy.

• Phenylhydrazones as ER Proteostasis Regulators

  2026-09-22

  The preprint identifies a covalent interaction between the phenylhydrazone compound AA263 and a subset of endoplasmic reticulum protein disulfide isomerases, providing a mechanistic basis for ATF6-linked proteostasis remodeling. Its next-generation analogs improve ATF6 activation and show functional correction of disease-associated protein folding and trafficking defects, although the findings remain pre-peer-review and require broader validation.

• Nigericin sodium salt: Practical Assay Setup

  2026-09-22

  Nigericin sodium salt is a potassium ionophore for controlled K+/H+ exchange, ion-gradient perturbation, and cytoplasmic pH regulation studies. This guide covers solvent handling, short-exposure assay design, platelet workflows, and QC while emphasizing that the compound is for research use only and is unsuitable for water- or DMSO-based preparations, diagnosis, or treatment.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-21

  The reference study shows that ATRX-deficient high-grade glioma cells are more vulnerable than ATRX-proficient counterparts to several receptor tyrosine kinase and PDGFR inhibitors. Its most actionable implication is that ATRX status should be considered when interpreting RTK-inhibitor trials and when designing combinations with temozolomide.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-09-21

  The reference study identifies ATRX deficiency as a potential determinant of response to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination experiments further show that ATRX status may influence temozolomide-based treatment responses, although clinical validation is still required.

7914 records 1/528 page Next 12345 下5页 Last page